The PLACID Trial in India: Convalescent Plasma Offers No Benefit to Reducing Mortality or Disease Progression

A national multi-site clinical trial in India, funded by the Indian Council of Medical Research (ICMR), found that the use of convalescent plasma fails to reduce mortality or even stop progression of severe COVID-19.&nbsp;Conducted at 39 trial site organizations (primarily hospitals and health centers) around the nation, the PLACID Trial&nbsp;was conducted between April 22 and July 14 to investigate the efficacy of convalescent plasma (CP) for the treatment of COVID-19.&nbsp;The prominent Indian study team suggests a prior measurement of neutralizing antibody titers in convalescent plasma donors and participating patients could likely contribute clarity and clarification to the role of CP in the ongoing management of SARS-CoV-2, the virus behind COVID-19.


